Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients

Modern Rheumatology

Volumn 21, Issue 1, 2011, Pages 16-23

  Urata, Yukitomo ^d   Uesato, Ryoko ^a   Tanaka, Dai ^a   Kowatari, Kenji ^a   Nitobe, Taisuke ^a   Nakamura, Yoshihide ^b   Motomura, Shigeru ^c  

^a Seihoku Central Hospital   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d NONE

Author keywords

Biologic; Hepatitis B virus; Reactivation of hepatitis B; Rheumatoid arthritis

Indexed keywords

ACTARIT; ADALIMUMAB; AURANOFIN; AUROTHIOMALATE; BUCILLAMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MIZORIBINE; PENICILLAMINE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; VIRUS DNA;

ADULT; AGED; ARTICLE; CORTICOSTEROID THERAPY; DNA DETERMINATION; DNA REPLICATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; VIRUS REACTIVATION; VIRUS REPLICATION;

AGED; ARTHRITIS, RHEUMATOID; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 79951952735     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0337-z     Document Type: Article

References (48)

1. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 61 62
2. AM Di Bisceglie 2009 Hepatitis B and hepatocellular carcinoma Hepatology 49 S56 S60 10.1002/hep.22962 19399807
3. JH Hoofnagle 2009 Reactivation of hepatitis B Hepatology 49 S156 S165 1:CAS:528:DC%2BD1MXlvFKqsLk%3D 10.1002/hep.22945 19399803
4. LH Calabrese NN Zein D Vassilopoulos 2006 Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 983 989 1:CAS:528: DC%2BD28XosFahur4%3D 10.1136/ard.2005.043257 16627542 (Pubitemid 44133258)
5. S Zingarelli P Airò M Frassi C Bazzani M Scarsi M Puoti 2008 Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases Reumatismo 60 22 27 1:STN:280:DC%2BD1c3ntFehtQ%3D%3D 18432322
6. P Ostuni C Botsios L Punzi P Sfriso S Todesco 2003 Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate Ann Rheum Dis 62 686 687 1:STN:280:DC%2BD3s3ot1Gnug%3D%3D 10.1136/ard.62.7.686 12810441 (Pubitemid 36760576)
7. DU Cansu T Kalifoglu C Korkmaz 2008 Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis J Rheumatol 35 421 424 1:CAS:528:DC%2BD1cXksFKjtr0%3D 18203328 (Pubitemid 351374414)
8. F Zoulim 2005 New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA J Hepatol 42 302 308 10.1016/j.jhep.2004.12.015 15710212 (Pubitemid 40254242)
9. B Rehermann C Ferrari C Pasquinelli FV Chisari 1996 The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response Nat Med 2 1104 1108 1:CAS:528:DyaK28Xmt1Wnu7s%3D 10.1038/nm1096-1104 8837608 (Pubitemid 26338629)
10. N Yuki T Nagaoka M Yamashiro K Mochizuki A Kaneko K Yamamoto, et al. 2003 Long-term histologic and virologic outcomes of acute self-limited hepatitis B Hepatology 37 1172 1179 1:CAS:528:DC%2BD3sXktVWnsb8%3D 10.1053/jhep.2003.50171 12717399 (Pubitemid 36538695)
11. W Yeo PJ Johnson 2006 Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy Hepatology 43 209 220 1:CAS:528:DC%2BD28XhvVSgu7o%3D 10.1002/hep.21051 16440366
12. K Kitano H Kobayashi M Hanamura K Furuta M Ueno A Rokuhara, et al. 2006 Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promoter region Eur J Haematol 77 255 258 1:CAS:528:DC%2BD28XhtVSku7nO 10.1111/j.1600-0609.2006.00678.x 16923112 (Pubitemid 44181390)
13. CK Hui WW Cheung HY Zhang WY Au YH Yueng AY Leung, et al. 2006 Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy Gastroenterology 131 59 68 1:CAS:528:DC%2BD28XnvF2gsL0%3D 10.1053/j.gastro.2006.04.015 16831590
14. T Sera Y Hiasa K Michitaka I Konishi K Matsuura Y Tokumoto, et al. 2006 Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab Intern Med 45 721 724 10.2169/internalmedicine.45.1590 16819252 (Pubitemid 44027603)
15. M Esteve C Saro F González-Huix F Suarez M Forné JM Viver 2004 Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis Gut 53 1363 1365 1:STN:280:DC%2BD2cvgt1Crsg%3D%3D 10.1136/gut.2004.040675 15306601 (Pubitemid 39120128)
16. S Ito K Nakazono A Murasawa Y Mita K Hata N Saito, et al. 2001 Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient Arthritis Rheum 44 339 342 1:STN:280:DC%2BD3M7lvV2qsQ%3D%3D 10.1002/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q 11229464 (Pubitemid 32207027)
17. PM Montiel JA Solis JA Chirinos B Casis F Sánchez S Rodríguez 2008 Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient Liver Int 28 718 720 10.1111/j.1478-3231.2007.01665.x 18433400 (Pubitemid 351541107)
18. S Madonia A Orlando D Scimeca M Olivo F Rossi M Cottone 2007 Occult hepatitis B and infliximab-induced HBV reactivation Inflamm Bowel Dis 13 508 509 10.1002/ibd.20035 17206687 (Pubitemid 46668261)
19. S Sasaki S Sato Y Kano, et al. 2009 Validity of COBAS TaqMan HBV Test v2.0 Igaku to Yakugaku 61 787 795 1:CAS:528:DC%2BD1MXhtVegtL3L (in Japanese)
20. G Raimondo T Pollicino I Cacciola G Squadrito 2007 Occult hepatitis B virus infection J Hepatol 46 160 170 10.1016/j.jhep.2006.10.007 17112622 (Pubitemid 44827430)
21. H Togashi C Hashimoto J Yokozawa A Suzuki K Sugahara T Saito, et al. 2008 What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol 49 17 24 1:CAS:528:DC%2BD1cXmvFels70%3D 10.1016/j.jhep.2008.03.019 18479773
22. R Liang GK Lau YL Kwong 1999 Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem J Clin Oncol 17 394 398 1:STN:280:DyaK1MzosFCnsg%3D%3D 10458258 (Pubitemid 29022418)
23. G Lalazar D Rund D Shouval 2007 Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 136 699 712 1:CAS:528:DC%2BD2sXjvFWmtb0%3D 10.1111/j.1365-2141.2006. 06465.x 17338776
24. GK Lau 2008 Hepatitis B reactivation after chemotherapy: two decades of clinical research Hepatol Int 2 152 162 10.1007/s12072-008-9056-3 19669300 (Pubitemid 351650143)
25. JS Lubel AG Testro PW Angus 2007 Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management Intern Med J 37 705 712 1:STN:280:DC%2BD2srntlCjsg%3D%3D 10.1111/j.1445-5994.2007.01479.x 17894766 (Pubitemid 47481164)
26. JR Bradley 2008 TNF-mediated inflammatory disease J Pathol 214 149 160 1:CAS:528:DC%2BD1cXhvFCktrY%3D 10.1002/path.2287 18161752 (Pubitemid 351160153)
27. ED Harris Jr 1990 Rheumatoid arthritis. Pathophysiology and implications for therapy N Engl J Med 322 1277 1289 10.1056/NEJM199005033221805 2271017 (Pubitemid 20152491)
28. LJ Gibbons KL Hyrich 2009 Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response BioDrug 23 111 124 1:CAS:528:DC%2BD1MXovFSnsbg%3D 10.2165/00063030-200923020-00004
29. KL Winthrop 2006 Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor Nat Clin Pract Rheumatol 2 602 610 1:CAS:528:DC%2BD28Xht1emtLnO 10.1038/ncprheum0336 17075599 (Pubitemid 44650948)
30. HM Daniels A Meager AL Eddleston GJ Alexander R Williams 1990 Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection Lancet 335 875 877 1:STN:280:DyaK3c3itVSksg%3D%3D 10.1016/0140-6736(90)90475-K 1969983 (Pubitemid 20136779)
31. JW Fang WW Shen A Meager JY Lau 1996 Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection Am J Gastroenterol 91 748 753 1:STN:280:DyaK287os1Kmtg%3D%3D 8677942 (Pubitemid 26117956)
32. JN Stoop AM Woltman PJ Biesta JG Kusters EJ Kuipers HL Janssen, et al. 2007 Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response Hepatology 46 699 705 1:CAS:528:DC%2BD2sXhtFWhsrzF 10.1002/hep.21761 17654744 (Pubitemid 47436115)
33. GH Wong DV Goeddel 1986 Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons Nature 323 819 822 1:CAS:528:DyaL28Xmt1Cgsrg%3D 10.1038/323819a0 2430188 (Pubitemid 17176583)
34. S Kasahara K Ando K Saito K Sekikawa H Ito T Ishikawa, et al. 2003 Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes J Virol 77 2469 2476 1:CAS:528: DC%2BD3sXpvVGntQ%3D%3D 10.1128/JVI.77.4.2469-2476.2003 12551985 (Pubitemid 36222771)
35. D Ganem AM Prince 2004 Hepatitis B virus infection-natural history and clinical consequences N Engl J Med 350 1118 1129 1:CAS:528:DC%2BD2cXitV2qurs%3D 10.1056/NEJMra031087 15014185 (Pubitemid 38298992)
36. G Herbein WA O'Brien 2000 Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis Proc Soc Exp Biol Med 223 241 257 1:CAS:528:DC%2BD3cXksVKqurY%3D 10.1046/j.1525-1373.2000.22335.x 10719836 (Pubitemid 30337778)
37. LG Guidotti T Ishikawa MV Hobbs B Matzke R Schreiber FV Chisari 1996 Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes Immunity 4 25 36 1:CAS:528:DyaK28Xos1Kltw%3D%3D 10.1016/S1074-7613(00)80295-2 8574849 (Pubitemid 26054933)
38. G Marinos NV Naoumov S Rossol F Torre PY Wong H Gallati, et al. 1995 Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection Gastroenterology 108 1453 1463 1:STN:280:DyaK2M3ks12kuw%3D%3D 10.1016/0016-5085(95)90694-0 7729638
39. SJ Chung JK Kim MC Park YB Park SK Lee 2009 Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy J Rheumatol 36 2416 2420 1:CAS:528:DC%2BD1MXhsFenurvK 10.3899/jrheum.081324 19797507
40. G Millonig M Kern O Ludwiczek K Nachbaur W Vogel 2006 Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 14 974 976
41. M Michel C Duvoux C Hezode D Cherqui 2003 Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease J Rheumatol 30 1624 1625 12858469 (Pubitemid 36835467)
42. D Wendling B Auge D Bettinger A Lohse G Le Huede S Bresson-Hadni, et al. 2005 Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy Ann Rheum Dis 64 788 789 1:STN:280:DC%2BD2M7pvFCitw%3D%3D 10.1136/ard.2004.031187 15834064 (Pubitemid 40559316)
43. PP Kaur VC Chan SN Berney 2008 Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports Clin Rheumatol 27 1069 1071 10.1007/s10067-008-0896-y 18521652
44. GT Sakellariou I Chatzigiannis 2007 Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection Clin Rheumatol 26 950 952 10.1007/s10067-006-0392-1 16865308 (Pubitemid 46951296)
45. N Nishimoto T Kishimoto 2006 Interleukin 6: from bench to bedside Nat Clin Pract Rheumatol 2 619 626 1:CAS:528:DC%2BD28Xht1emtLnI 10.1038/ncprheum0338 17075601 (Pubitemid 44650950)
46. S Kakumu T Shinagawa T Ishikawa K Yoshioka T Wakita Y Ito, et al. 1991 Serum interleukin 6 levels in patients with chronic hepatitis B Am J Gastroenterol 86 1804 1808 1:STN:280:DyaK38%2FnsVCltQ%3D%3D 1962626
47. W Yeo TC Chan NW Leung WY Lam FK Mo MT Chu, et al. 2009 Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 605 611 1:CAS:528:DC%2BD1MXivFyju7s%3D 10.1200/JCO.2008.18.0182 19075267
48. CJ Chen HI Yang J Su CL Jen SL You SN Lu, et al. 2006 REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 10.1001/jama.295.1.65 16391218 (Pubitemid 43042691)